First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
Authors
Keywords
-
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2021-03-08
DOI
10.1080/14737167.2021.1899813
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
- (2020) A.S. Mansfield et al. ANNALS OF ONCOLOGY
- FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1
- (2020) Preeti Narayan et al. CLINICAL CANCER RESEARCH
- Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France
- (2020) Sivignon Marine et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
- (2020) Dong Ding et al. ADVANCES IN THERAPY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
- (2020) Na Li et al. Cancer Management and Research
- Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
- (2019) Umang Ondhia et al. JOURNAL OF MEDICAL ECONOMICS
- How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non–Small-Cell Lung Cancer
- (2019) Solange Peters et al. ANNALS OF ONCOLOGY
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer
- (2019) Kexun Zhou et al. LUNG CANCER
- First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis
- (2019) XiaoMin Wan et al. CANCER
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- (2019) Edward B. Garon et al. JOURNAL OF CLINICAL ONCOLOGY
- Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
- (2019) Rui-Mei Feng et al. Cancer Communications
- Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
- (2019) Qiao Liu et al. CLINICAL DRUG INVESTIGATION
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
- (2018) Xiaohua Gu et al. LUNG CANCER
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Health state utilities in non-small cell lung cancer: An international study
- (2016) Beenish Nafees et al. Asia-Pacific Journal of Clinical Oncology
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Model Parameter Estimation and Uncertainty Analysis
- (2012) Andrew H. Briggs et al. MEDICAL DECISION MAKING
- Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting
- (2012) Bin Wu et al. PLoS One
- Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung
- (2012) Elizabeth A. Handorf et al. Journal of Oncology Practice
- Improved curve fits to summary survival data: application to economic evaluation of health technologies
- (2011) Martin W Hoyle et al. BMC Medical Research Methodology
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More